Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015

This article was originally published in The Tan Sheet

Executive Summary

Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.

Advertisement

Related Content

RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health
RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health
Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers
Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers
Perrigo Growth Trajectory Traverses Manufacturing, Licensing Headwinds
Perrigo Growth Trajectory Traverses Manufacturing, Licensing Headwinds
Sanofi Sues FDA To Stop Publication Of Nasacort Labeling Before Launch
Martek/Mead Agreement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS107059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel